AGEN Agenus Inc.

3.78
-0.06  -2%
Previous Close 3.84
Open 3.86
Price To Book -2.61
Market Cap 519,226,383
Shares 137,361,477
Volume 642,628
Short Ratio
Av. Daily Volume 1,390,805
Stock charts supplied by TradingView

NewsSee all news

  1. Agenus Announces the Appointment of Dr. Jennifer Buell to the position of President and COO

    LEXINGTON, Mass., Jan. 9, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of agents that activate immune response to cancers, is pleased to announce the appointment

  2. Agenus Commences Phase 1 trial with AGEN1223

    LEXINGTON, Mass., Jan. 8, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of agents that activate immune response to cancers, announced the dosing of the first

  3. Agenus Commences Combination Trial of its Next-Gen CTLA-4 with its PD-1 Antibody

    LEXINGTON, Mass., Dec. 19, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, today announced

  4. Agenus to Host R&D Day November 15, 2019

    LEXINGTON, Mass., Nov. 12, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, announced that it

  5. UroGen Pharma Announces Exclusive License Agreement with Agenus Inc to Advance Treatment of Urinary Tract Cancers

    UroGen to Develop and Commercialize Zalifrelimab (AGEN1884, anti-CTLA-4 antibody) with UGN-201 for High-Grade Non-Muscle Invasive Bladder Cancer UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 trial ongoing.
AGEN2034 and AGEN1884
Solid tumors
BLA filing due 2020.
Zalifrelimab - AGEN1884 (anti-CTLA-4)
Solid cancers
Approval announced October 20, 2017.
Shingrix
Shingles
Subset analysis of Phase I dose escalation trial presented at SITC November 8, 2019.
AGEN2034 (anti-PD-1)
Cervical cancer
Phase 1 combination with balstilimab trial initiation announced December 19, 2019.
AGEN1181 - 2nd gen CTLA
Advanced cancer

Latest News

  1. Agenus Announces the Appointment of Dr. Jennifer Buell to the position of President and COO

    LEXINGTON, Mass., Jan. 9, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of agents that activate immune response to cancers, is pleased to announce the appointment

  2. Agenus Commences Phase 1 trial with AGEN1223

    LEXINGTON, Mass., Jan. 8, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of agents that activate immune response to cancers, announced the dosing of the first

  3. Agenus Commences Combination Trial of its Next-Gen CTLA-4 with its PD-1 Antibody

    LEXINGTON, Mass., Dec. 19, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, today announced

  4. Agenus to Host R&D Day November 15, 2019

    LEXINGTON, Mass., Nov. 12, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, announced that it

  5. UroGen Pharma Announces Exclusive License Agreement with Agenus Inc to Advance Treatment of Urinary Tract Cancers

    UroGen to Develop and Commercialize Zalifrelimab (AGEN1884, anti-CTLA-4 antibody) with UGN-201 for High-Grade Non-Muscle Invasive Bladder Cancer UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical

  6. Agenus receives $10M from UroGen Pharma for rights to Zalifrelimab (CTLA-4) for intravesical treatment of urinary tract cancers

    LEXINGTON, Mass., Nov. 11, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, announced today

  7. Agenus Provides Corporate Update with Third Quarter 2019 Financial Results

    LEXINGTON, Mass., Nov. 4, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1, and cancer vaccines provided a

  8. Agenus to Report Third Quarter 2019 Financial Results on November 4, 2019 and Host Conference Call and Webcast

    LEXINGTON, Mass., Oct. 31, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its third quarter 2019 financial

  9. Agenus to Present at the 2019 Cantor Global Healthcare Conference on October 4, 2019

    LEXINGTON, Mass., Sept. 30, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, announced today

  10. VBI Vaccines Announces Phase 2a Clinical Evaluation of VBI-1901 Cancer Vaccine Candidate in Combination with GSK's AS01B Adjuvant System in Recurrent Glioblastoma Patients

    - VBI is the first biopharma company to collaborate with GSK to assess AS01B adjuvant system as part of a therapeutic cancer vaccine candidate - Combination will be tested in additional study arm in Part B of VBI's